Abstract:Background: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with a poor but heterogeneous prognosis. Although the ALS Functional Rating Scale (ALSFRS) has been most commonly used, the decreases in ALSFRS do not follow a unitary linear trend and may be affected by factors other than disease condition. Group-based trajectory modeling (GBTM) is a method that can take the heterogeneity of declines in ALSFRS into consideration. We analyzed the 16-year trajectory of ALSFRS of patients in China using the GBTM method, and explored possible reasons for differences in the trajectories.Methods: 3,257 patients with sporadic ALS from January 2005 to May 2021 were recruited. ALSFRS scores were the dependent variable in the GBTM. To evaluate whether our results were transferable to other populations, Answer ALS and Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) were used as validation datasets. The baseline characteristics and laboratory indicators in different trajectory groups were compared. A Cox proportional hazards model was used to examine the association between primary outcomes and trajectory groups.Results: A model with four groups (rapid, moderate, slow, and very slow progression) was adopted. The four groups differed in sex (P=0.002), age at onset (P<0.001), diagnostic delay (P<0.001), phenotype (P<0.001), riluzole use (P=0.001), onset site (P<0.001), cerebrospinal fluid (CSF) protein levels (P=0.044), and neutrophil-to-lymphocyte ratio (NLR; P=0.011). Compared with the moderate progression group, the rapid progression group displayed an increased risk of progression to respiratory insufficiency or death (hazard ratio [HR]: 1.66, 95% confidence interval [CI]: 1.41 to 1.97), but the very slow progression group (HR: 0.06, 95% CI: 0.02 to 0.26) had a decreased risk. The trajectory groups with faster progression had a higher NLR and higher total protein in the CSF.Interpretation: This study provides a novel prognosis prediction method using the ALSFRS score trajectory. Notably, the higher NLR and higher total protein in the CSF of the trajectory groups with faster progression suggested that neuroinflammation may play a crucial role in ALS progression.Funding Information: Lu Chen has received the funding from the Peking University Medicine Fund of Fostering Young Scholars’ Scientific & Technological Innovation supported by the Fundamental Research Funds for the Central Universities [Grant number BMU2022PY001]. Shengfeng Wang has received the funding from the Peking University Medicine Fund for World’s Leading Discipline or Discipline Cluster Development supported by the Fundamental Research Funds for the Central Universities [Grant number BMU2021YJ035]. Siyan Zhan has received the funding from the Special Project for Director, China Center for Evidence Based Traditional Chinese Medicine [Grant number 2020YJSZX-2]. Dongsheng Fan has received the fundings from the National Natural Science Foundation of China (NSFC) under Grant [Number 81873784; 82071426].Declaration of Interests: None.Ethics Approval Statement: The protocol was approved by the institutional ethics committee of PUTH (IRB. No 00006761), and written informed consent was obtained from each patient.

Multistep modeling applied to a Malaysian ALS registry

Amyotrophic lateral sclerosis established as a multistep process across phenotypes

Identifying patterns in amyotrophic lateral sclerosis progression from sparse longitudinal data

Harnessing Big Data in Amyotrophic Lateral Sclerosis: Machine Learning Applications for Clinical Practice and Pharmaceutical Trials

Machine learning and brain-computer interface approaches in prognosis and individualized care strategies for individuals with amyotrophic lateral sclerosis: A systematic review

Network spreading and local biological vulnerability in amyotrophic lateral sclerosis

Mismatch between clinically defined classification of ALS stage and the burden of cerebral pathology

Pathomechanistic Networks of Motor System Injury in Amyotrophic Lateral Sclerosis

Improving prediction models of amyotrophic lateral sclerosis (ALS) using polygenic, pre-existing conditions, and survey-based risk scores in the UK Biobank

The Miami Framework for ALS and related neurodegenerative disorders: an integrated view of phenotype and biology

From Mouse Models to Human Disease: An Approach for Amyotrophic Lateral Sclerosis

Alzheimer’s disease as a multistage process: an analysis from a population-based cohort study

Multicentre, prospective registry study of amyotrophic lateral sclerosis in mainland China (CHALSR): study protocol

Progress in clinical diagnosis of amyotrophic lateral sclerosis

Whole-exome Sequencing in Amyotrophic Lateral Sclerosis Suggests NEK1 is a Risk Gene in Chinese

Author Correction: Common and Rare Variant Association Analyses in Amyotrophic Lateral Sclerosis Identify 15 Risk Loci with Distinct Genetic Architectures and Neuron-Specific Biology

Amyotrophic Lateral Sclerosis Genetic Studies

Different Patterns of Structural Network Impairments in Two Amyotrophic Lateral Sclerosis Subtypes Driven by 18F-FDG PET/MR Hybrid Imaging

Amyotrophic lateral sclerosis and motor neuron syndromes in Asia.

Patient journey to a specialist amyotrophic lateral sclerosis multidisciplinary clinic: an exploratory study

Long-Term Longitudinal Progression Pattern of Amyotrophic Lateral Sclerosis: A Trajectory Analysis of a 16-Year Cohort in China